CDIO Cardio Diagnostics Holdings, Inc.

Overview and Growth

Fiscal 2025 results for Cardio Diagnostics Holdings, Inc. combined $14.82K of revenue with net loss of $6.50M and an operating cash outflow of $5.73M. Revenue of $14.82K sets the scale for evaluating how effectively sales translated into profit and cash during the year. The top line contracted 57.5% from $34.89K in fiscal 2024; this top-line contraction left the company with a smaller revenue base. On a per-share basis, diluted EPS was -$3.71, which connects the reported earnings outcome with the company’s diluted share count. Diluted shares averaged 1.75M; this is the reported share base over which the company’s diluted per-share earnings were spread. Diluted shares moved 95.4% from 896.42K in fiscal 2024, leaving the current share base higher year over year. At period end, total assets were $7.77M, framing the scale of the company’s operating and financing commitments. Asset turnover was 0.0x, relating the company’s annual revenue directly to the total assets reported at the period end.

Profitability

The reported operating result was an operating loss of $6.48M, reflecting costs that exceeded gross profit. The bottom-line result was a net loss of $6.50M after operating, financing, tax, and other recognized items. Negative EBITDA totaled $6.42M, confirming that the earnings deficit remained before depreciation and amortization. The pretax result was a loss of $6.50M, establishing the deficit before tax effects. The loss-to-equity relationship was 93.2%, placing the bottom-line deficit against shareholder capital. The net loss equaled 83.7% of period-end assets, showing the deficit relative to the asset base. The bottom-line deficit decreased from $8.38M in fiscal 2024 to $6.50M.

Liquidity and Capital Structure

The company held $7.77M of assets against $793.06K of liabilities and $6.97M of equity, revealing how the asset base was financed. At period end, current assets of $5.92M compared with current liabilities of $604.84K, defining the company’s short-term resource position. At 9.79x, the current ratio shows that short-term assets were greater than short-term liabilities at period end. The company held $0.00 in cash and equivalents, a narrower liquidity measure than total current assets. Measured only with cash and equivalents, coverage of current liabilities was 0.0%, excluding receivables and other current assets. Equity equaled 89.8% of assets, showing the shareholder-capital layer within the company’s balance sheet. Relative to total assets, liabilities measured 10.2%, complementing the separate equity-based view of the company’s capital structure. Measured against total assets, cash and equivalents represented 0.0%, a balance-sheet composition measure rather than a liquidity forecast. The asset base changed 26.8% from $10.62M in fiscal 2024, leaving current total assets lower year over year. Book equity was 27.0% lower than fiscal 2024 equity of $9.56M, showing how shareholder capital changed year over year.

Cash Flow and Earnings Quality

The company reported an operating cash outflow of $5.73M, rather than cash generation from operations. Capital expenditures used $187.32K in addition to the operating cash outflow, increasing the total cash consumed by operations and investment during the period. The company recorded a $5.91M cash deficit after capital spending for the period. The free-cash-flow deficit equaled 76.2% of total assets, placing the cash shortfall against the company’s resource base. The operating cash outflow widened to $5.73M from $4.99M in fiscal 2024.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Oct 21, 2026.